A Phase 2 interventional study of Saroglitazar Magnesium 4 mg Tablet and Placebo in Non-alcoholic Fatty Liver Disease in Women With PCOS, sponsored by Zydus Therapeutics Inc.. Terminated at 19 sites in 2 countries. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 217th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 251st registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 62 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is close to the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
This study is registered under Zydus Therapeutics Inc., one of the names counted as Zydus Lifesciences Limited. Under that name alone:
Zydus Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Zydus Lifesciences Limited has 7 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS.
This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS.
The study will be conducted over a period of up to 34 weeks and will include Screening (Days -28 to -7) Phase, a 24-week Treatment Phase following randomization on Day 1.
The primary endpoint of the study is change in hepatic fat content from baseline following 24 weeks of treatment as measured by MRI-PDFF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Previously confirmed diagnosis of PCOS:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Saroglitazar Magnesium once daily in the morning before breakfast
Drug: Saroglitazar Magnesium 4 mg Tablet
Placebo tablet once daily in the morning before breakfast
Drug: Placebo
Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
Also known as: Not any
Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
Also known as: Not any
Hepatic Fat Content
Change in hepatic fat content from baseline following 24 weeks of treatment as measured by Magnetic Resonance Imaging-derived Proton Density-fat Fraction (MRI-PDFF)
Time frame: Baseline and Week 24
Liver Enzymes/Liver Function Tests
Changes from baseline to week 12 and week 24 in Alkaline phosphatase
Time frame: Baseline, Week 12, and Week 24
Liver Enzymes/Liver Function Tests
Changes from baseline to week 12 and week 24 in Alanine aminotransferase
Time frame: Baseline, Week 12, and Week 24
Liver Enzymes/Liver Function Tests
Changes from baseline to week 12 and week 24 in Aspartate Aminotransferase
Time frame: Baseline, Week 12, and Week 24
Liver Enzymes/Liver Function Tests
Changes from baseline to week 12 and week 24 in gamma-glutamyl transferase
Time frame: Baseline, Week 12, and Week 24
Liver Enzymes/Liver Function Tests
Changes from baseline to week 12 and week 24 in serum protein
Time frame: Baseline, Week 12, and Week 24
Liver Enzymes/Liver Function Tests
Changes from baseline to week 12 and week 24 in albumin
Time frame: Baseline, Week 12, and Week 24
Liver Enzymes/Liver Function Tests
Changes from baseline to week 12 and week 24 in total bilirubin.
Time frame: Baseline, Week 12, and Week 24
Insulin Resistance
Evaluation of HOMA of Insulin Resistance Index determines insulin resistance and estimates insulin sensitivity, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance
Time frame: Baseline, Week 12, and Week 24
Liver Injury
Changes from baseline to week 24 in Liver Injury, including Cytokeratin (CK)-18. CK18 \[M30\] and CK-18 \[M-65\] were measured as biomarkers of hepatocyte apoptosis. Both are important indicators for liver tissue conditions and effectively reflect hepatocyte damage. A negative change from baseline indicates a decrease in hepatocyte apoptosis or a decrease in hepatocyte damage.
Time frame: Baseline and Week 24
Liver Injury
Changes from baseline to week 24 in high-sensitivity C-reactive protein (hs-CRP)
Time frame: Baseline and Week 24
Liver Injury
Changes from baseline to week 24 in Tumor necrosis factor (TNFα)
Time frame: Baseline and Week 24
Liver Stiffness
Changes from baseline to week 24 in liver stiffness measured by transient elastography/FibroScan
Time frame: Baseline and Week 24
Controlled Attenuation Parameter
Changes from baseline to week 24 in controlled attenuation parameter measured by transient elastography/ FibroScan
Time frame: Baseline and Week 24
Body Mass Index (BMI)
Changes from baseline to week 12 and week 24 in Body mass index
Time frame: Baseline, Week 12, and Week 24
Waist Circumference
Changes from baseline to week 12 and week 24 in waist circumference
Time frame: Baseline, Week 12, and Week 24
Changes From Baseline to Week 24 in MRI-derived Measures of Total Liver Fat Index
MRI-derived measures of total liver fat index. Total liver volume: The total liver volume was calculated through a process requiring segmentation image analysis. Liver volume was calculated after complete segmentation by summing the liver surface area at each segmented slice and then multiplying this sum by individual slice thickness, in milliliters (mL). Total liver fat index: The total liver fat index (TLFI, units: % mL) took into consideration the volume of liver from which proton-density fat fraction was derived. It was calculated as the product of liver volume and the liver mean proton-density fat fraction across all liver segments.
Time frame: Baseline and Week 24
Changes From Baseline to Week 24 in MRI-derived Measures of Total Liver Volume
MRI-derived measures of total liver volume (Liver volume will be calculated after complete segmentation by summing the liver surface area at each segmented slice, and then multiplying this sum by individual slice thickness, in millilitres \[mL\])
Time frame: Baseline and Week 24
Lipid and Lipoprotein Levels
Changes from baseline to week 12 and week 24 in Triglyceride (TG)
Time frame: Baseline, Week 12, and Week 24
Lipid and Lipoprotein Levels
Changes from baseline to week 12 and week 24 in Total cholesterol (TC)
Time frame: Baseline, Week 12, and Week 24
Lipid and Lipoprotein Levels
Changes from baseline to week 12 and week 24 in High-density lipoprotein
Time frame: Baseline, Week 12, and Week 24
Lipid and Lipoprotein Levels
Changes from baseline to week 12 and week 24 in Low-density lipoprotein (LDL)
Time frame: Baseline, Week 12, and Week 24
Lipid and Lipoprotein Levels
Changes from baseline to week 12 and week 24 in Small dense low density lipoprotein (sdLDL)
Time frame: Baseline, Week 12, and Week 24
Lipid and Lipoprotein Levels
Changes from baseline to week 12 and week 24 in Very low density lipoprotein (VLDL)
Time frame: Baseline, Week 12, and Week 24
Lipid and Lipoprotein Levels
Changes from baseline apolipoprotein A
Time frame: Baseline, Week 12, and Week 24
Lipid and Lipoprotein Levels
Changes from baseline in apolipoprotein B
Time frame: Baseline, Week 12, and Week 24
Sex Hormone Binding Globulin (SHBG) Level
Changes from baseline in SHBG level
Time frame: Baseline, Week 12, and Week 24
Ovarian Function
Changes from baseline in 17-hydroxyprogesterone
Time frame: Baseline, Week 12, and Week 24
Ovarian Function
Changes from baseline in Total testosterone
Time frame: Baseline, Week 12, and Week 24
Ovarian Function
Changes from baseline in free testosterone
Time frame: Baseline, Week 12, and Week 24
Ovarian Function
Changes from baseline in follicle-stimulating hormone (FSH)
Time frame: Baseline, Week 12, and Week 24
Ovarian Function
Changes from baseline in luteinizing hormone (LH)
Time frame: Baseline, Week 12, and Week 24
Ovarian Function
Changes from baseline in LH-to-FSH ratio
Time frame: Baseline, Week 12, and Week 24
Ovarian Function
Changes from baseline in estradiol
Time frame: Baseline, Week 12, and Week 24
Changes From Baseline to Week 12 and Week 24 in Free Androgen Index
Free androgen index is a ratio used to determine abnormal androgen status in humans, measured by Total testosterone level divided by the sex hormone binding globulin (SHBG) level, and then multiplying by a constant, usually 100. A higher score indicates a worse outcome (more androgenic).
Time frame: Baseline, Week 12, and Week 24
Peak Plasma Concentration [Cmax] (For Single Dose)
Pharmacokinetics of Saroglitazar following first dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Time to Reach Peak Plasma Concentration [Tmax] (For Single Dose)
Pharmacokinetics of Saroglitazar following first dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Area Under Plasma Concentration vs. Time Curve Till the Last Time Point [AUC0-t] (For Single Dose)
Pharmacokinetics of Saroglitazar following first dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Area Under Plasma Concentration vs. Time Curve Extrapolated to the Infinity (AUC0-∞) After First Dose (For Single Dose)
Pharmacokinetics of Saroglitazar following first dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Area Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval (AUCtau) After First Dose (For Single Dose)
Pharmacokinetics of Saroglitazar following first dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Elimination Rate Constant [Kel] (For Single Dose)
Pharmacokinetics of Saroglitazar following first dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Elimination Half-life [tHalf] (For Single Dose)
Pharmacokinetics of Saroglitazar following first dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (Visit 3)
Apparent Volume of Distribution [Vd/F] (For Single Dose)
Pharmacokinetics of Saroglitazar following first dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Apparent Clearance [CL/F] (For Single Dose)
Pharmacokinetics of Saroglitazar following first dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Peak Plasma Concentration [Cmax,ss] (For Multiple Dose)
Pharmacokinetics of Saroglitazar following last dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0,10.0, and 24 hours post-dose of Last dose (Visit 8)
Time to Reach Peak Plasma Concentration [Tmax,ss] (For Multiple Dose)
Pharmacokinetics of Saroglitazar following last dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Area Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval (AUCtau) After Last Dose (For Multiple Dose)
Pharmacokinetics of Saroglitazar following last dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Elimination Rate Constant [Kel,ss] (For Multiple Dose)
Pharmacokinetics of Saroglitazar following last dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (Visit 8)
Elimination Half-life [Thalf,ss] (For Multiple Dose)
Pharmacokinetics of Saroglitazar following last dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Apparent Volume of Distribution [Vd/F,ss] (For Multiple Dose)
Pharmacokinetics of Saroglitazar following last dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Apparent Clearance [CL/F,ss] (For Multiple Dose)
Pharmacokinetics of Saroglitazar following last dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Minimal or Trough Plasma Concentration [Cmin] (For Multiple Dose)
Pharmacokinetics of Saroglitazar following last dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Fluctuation Index (For Multiple Dose)
Pharmacokinetics of Saroglitazar following the last dose. It is calculated as (Cmax - Cmin) / Cavg. The value has been multiplied by 100, hence has been expressed in percentage unit; where Cmax is the Maximum measured plasma concentration at steady state, Cmin is Minimal or trough plasma concentration at steady state, and Cavg is Average concentration = AUCtau,ss /tau.
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Accumulation Index Calculated as a Ratio of AUCtau (Last Dose)/AUCtau (First Dose) (For Multiple Dose)
Pharmacokinetics of Saroglitazar following last dose
Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
| Milestone | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Started | 30 | 30 |
| Completed | 26 | 26 |
| Not completed | 4 | 4 |
Change in hepatic fat content from baseline following 24 weeks of treatment as measured by Magnetic Resonance Imaging-derived Proton Density-fat Fraction (MRI-PDFF)
| percentage of liver fat | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Hepatic Fat Content | -3.1741 ± 1.01800 | -0.3499 ± 1.06137 |
Changes from baseline to week 12 and week 24 in Alkaline phosphatase
| U/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -22.64 ± 1.954 | -3.91 ± 2.083 |
| Week 24 | -20.07 ± 2.520 | -1.66 ± 2.627 |
Changes from baseline to week 12 and week 24 in Alanine aminotransferase
| U/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -22.00 ± 4.586 | -4.72 ± 4.894 |
| Week 24 | -25.73 ± 4.276 | -8.30 ± 4.462 |
Changes from baseline to week 12 and week 24 in Aspartate Aminotransferase
| U/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -9.97 ± 4.233 | -3.31 ± 4.514 |
| Week 24 | -11.27 ± 4.437 | -2.88 ± 4.627 |
Changes from baseline to week 12 and week 24 in gamma-glutamyl transferase
| U/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -22.62 ± 2.629 | -1.52 ± 2.807 |
| Week 24 | -21.46 ± 2.545 | -2.37 ± 2.656 |
Changes from baseline to week 12 and week 24 in serum protein
| g/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | 0.01 ± 0.072 | 0.02 ± 0.077 |
| Week 24 | -0.14 ± 0.071 | 0.03 ± 0.074 |
Changes from baseline to week 12 and week 24 in albumin
| g/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | 1.06 ± 0.477 | -0.39 ± 0.510 |
| Week 24 | 0.06 ± 0.485 | -0.15 ± 0.507 |
Changes from baseline to week 12 and week 24 in total bilirubin.
| mg/dL | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -0.076 ± 0.0294 | -0.008 ± 0.0313 |
| Week 24 | -0.066 ± 0.0290 | -0.004 ± 0.0302 |
Evaluation of HOMA of Insulin Resistance Index determines insulin resistance and estimates insulin sensitivity, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance
| Index | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -1.983 ± 1.2192 | 1.081 ± 1.3004 |
| Week 24 | 0.498 ± 2.1910 | 4.303 ± 2.2852 |
Changes from baseline to week 24 in Liver Injury, including Cytokeratin (CK)-18. CK18 \[M30\] and CK-18 \[M-65\] were measured as biomarkers of hepatocyte apoptosis. Both are important indicators for liver tissue conditions and effectively reflect hepatocyte damage. A negative change from baseline indicates a decrease in hepatocyte apoptosis or a decrease in hepatocyte damage.
| U/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| M30 | -238.801 ± 69.9009 | -92.160 ± 72.8890 |
| M65 | -260.232 ± 100.6148 | -72.273 ± 104.9207 |
Changes from baseline to week 24 in high-sensitivity C-reactive protein (hs-CRP)
| mg/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Liver Injury | -1.00 ± 1.381 | 0.55 ± 1.440 |
Changes from baseline to week 24 in Tumor necrosis factor (TNFα)
| ng/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Liver Injury | 0.109 ± 0.2711 | 0.587 ± 0.2827 |
Changes from baseline to week 24 in liver stiffness measured by transient elastography/FibroScan
| kPa | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Liver Stiffness | -0.75 ± 0.953 | 1.67 ± 0.994 |
Changes from baseline to week 24 in controlled attenuation parameter measured by transient elastography/ FibroScan
| dB/m | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Controlled Attenuation Parameter | -18.84 ± 9.119 | -3.40 ± 9.521 |
Changes from baseline to week 12 and week 24 in Body mass index
| kg/m^2 | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | 0.101 ± 0.2817 | 0.272 ± 0.3003 |
| Week 24 | 0.273 ± 0.3132 | -0.066 ± 0.3266 |
Changes from baseline to week 12 and week 24 in waist circumference
| cm | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | 1.285 ± 0.9879 | 1.142 ± 1.0783 |
| Week 24 | 1.607 ± 0.8919 | 1.127 ± 0.9300 |
MRI-derived measures of total liver fat index. Total liver volume: The total liver volume was calculated through a process requiring segmentation image analysis. Liver volume was calculated after complete segmentation by summing the liver surface area at each segmented slice and then multiplying this sum by individual slice thickness, in milliliters (mL). Total liver fat index: The total liver fat index (TLFI, units: % mL) took into consideration the volume of liver from which proton-density fat fraction was derived. It was calculated as the product of liver volume and the liver mean proton-density fat fraction across all liver segments.
| %mL | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Changes From Baseline to Week 24 in MRI-derived Measures of Total Liver Fat Index | -78.493 ± 38.0001 | -8.963 ± 37.1636 |
MRI-derived measures of total liver volume (Liver volume will be calculated after complete segmentation by summing the liver surface area at each segmented slice, and then multiplying this sum by individual slice thickness, in millilitres \[mL\])
| mL | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Changes From Baseline to Week 24 in MRI-derived Measures of Total Liver Volume | -66.886 ± 70.3776 | -36.176 ± 68.8178 |
Changes from baseline to week 12 and week 24 in Triglyceride (TG)
| mg/dL | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -41.535 ± 12.3535 | -21.665 ± 13.1733 |
| Week 24 | -47.886 ± 15.8642 | 14.724 ± 16.5423 |
Changes from baseline to week 12 and week 24 in Total cholesterol (TC)
| mg/dL | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -16.807 ± 3.8832 | -6.992 ± 4.1447 |
| Week 24 | -22.650 ± 3.7464 | -3.120 ± 3.9095 |
Changes from baseline to week 12 and week 24 in High-density lipoprotein
| mg/dL | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | 2.327 ± 1.3110 | -0.599 ± 1.3986 |
| Week 24 | 0.676 ± 1.4851 | -1.561 ± 1.5491 |
Changes from baseline to week 12 and week 24 in Low-density lipoprotein (LDL)
| mg/dL | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -10.318 ± 3.7934 | -4.821 ± 4.0492 |
| Week 24 | -13.457 ± 3.0454 | -4.938 ± 3.1785 |
Changes from baseline to week 12 and week 24 in Small dense low density lipoprotein (sdLDL)
| mg/dL | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -6.918 ± 2.0576 | -4.889 ± 2.1943 |
| Week 24 | -9.000 ± 1.9510 | -2.574 ± 2.0346 |
Changes from baseline to week 12 and week 24 in Very low density lipoprotein (VLDL)
| mg/dL | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -7.102 ± 2.5927 | -3.521 ± 2.7645 |
| Week 24 | -8.736 ± 2.9168 | 3.452 ± 3.0413 |
Changes from baseline apolipoprotein A
| mg/dL | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | 4.486 ± 3.8760 | 2.130 ± 4.1326 |
| Week 24 | -2.830 ± 3.1112 | -1.272 ± 3.2442 |
Changes from baseline in apolipoprotein B
| mg/dL | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -10.673 ± 2.7834 | -3.508 ± 2.9723 |
| Week 24 | -13.146 ± 2.3060 | -3.233 ± 2.4071 |
Changes from baseline in SHBG level
| nmol/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | 17.182 ± 13.1496 | 27.506 ± 14.0281 |
| Week 24 | -3.882 ± 8.0521 | 8.286 ± 8.3982 |
Changes from baseline in 17-hydroxyprogesterone
| ng/dL | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | 8.800 ± 9.7348 | -4.819 ± 10.3892 |
| Week 24 | -10.325 ± 6.8372 | -2.168 ± 7.1337 |
Changes from baseline in Total testosterone
| nmol/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -0.173 ± 0.1134 | -0.171 ± 0.1209 |
| Week 24 | -0.231 ± 0.1182 | -0.073 ± 0.1233 |
Changes from baseline in free testosterone
| nmol/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -0.005 ± 0.0028 | -0.009 ± 0.0030 |
| Week 24 | -0.005 ± 0.0028 | -0.003 ± 0.0029 |
Changes from baseline in follicle-stimulating hormone (FSH)
| IU/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -0.892 ± 0.3356 | -1.722 ± 0.3580 |
| Week 24 | -0.689 ± 0.3196 | -1.125 ± 0.3334 |
Changes from baseline in luteinizing hormone (LH)
| IU/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -1.140 ± 0.8881 | -1.632 ± 0.9467 |
| Week 24 | -1.305 ± 1.2020 | 0.140 ± 1.2532 |
Changes from baseline in LH-to-FSH ratio
| Ratio | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -0.230 ± 0.1731 | 0.064 ± 0.1808 |
| Week 24 | -0.324 ± 0.2226 | 0.136 ± 0.2326 |
Changes from baseline in estradiol
| pmol/L | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -57.237 ± 41.4020 | -24.045 ± 44.1354 |
| Week 24 | -105.380 ± 65.5983 | 17.209 ± 68.3930 |
Free androgen index is a ratio used to determine abnormal androgen status in humans, measured by Total testosterone level divided by the sex hormone binding globulin (SHBG) level, and then multiplying by a constant, usually 100. A higher score indicates a worse outcome (more androgenic).
| Ratio | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| Week 12 | -0.371 ± 0.1637 | -0.483 ± 0.1746 |
| Week 24 | -0.253 ± 0.1742 | -0.256 ± 0.1816 |
Pharmacokinetics of Saroglitazar following first dose
| ng/mL | Saroglitazar Magnesium 4 mg |
|---|---|
| Peak Plasma Concentration [Cmax] (For Single Dose) | 120.250 ± 49.997 |
Pharmacokinetics of Saroglitazar following first dose
| hour | Saroglitazar Magnesium 4 mg |
|---|---|
| Time to Reach Peak Plasma Concentration [Tmax] (For Single Dose) | 1.902 ± 1.103 |
Pharmacokinetics of Saroglitazar following first dose
| ng*hr/mL | Saroglitazar Magnesium 4 mg |
|---|---|
| Area Under Plasma Concentration vs. Time Curve Till the Last Time Point [AUC0-t] (For Single Dose) | 486.033 ± 188.320 |
Pharmacokinetics of Saroglitazar following first dose
| ng/mL*hr | Saroglitazar Magnesium 4 mg |
|---|---|
| Area Under Plasma Concentration vs. Time Curve Extrapolated to the Infinity (AUC0-∞) After First Dose (For Single Dose) | 473.771 ± 182.430 |
Pharmacokinetics of Saroglitazar following first dose
| ng*hr/mL | Saroglitazar Magnesium 4 mg |
|---|---|
| Area Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval (AUCtau) After First Dose (For Single Dose) | 491.981 ± 192.373 |
Pharmacokinetics of Saroglitazar following first dose
| 1/hr | Saroglitazar Magnesium 4 mg |
|---|---|
| Elimination Rate Constant [Kel] (For Single Dose) | 0.144 ± 0.057 |
Pharmacokinetics of Saroglitazar following first dose
| hr | Saroglitazar Magnesium 4 mg |
|---|---|
| Elimination Half-life [tHalf] (For Single Dose) | 5.317 ± 1.559 |
Pharmacokinetics of Saroglitazar following first dose
| L | Saroglitazar Magnesium 4 mg |
|---|---|
| Apparent Volume of Distribution [Vd/F] (For Single Dose) | 77.890 ± 42.887 |
Pharmacokinetics of Saroglitazar following first dose
| L/hr | Saroglitazar Magnesium 4 mg |
|---|---|
| Apparent Clearance [CL/F] (For Single Dose) | 9.305 ± 3.599 |
Pharmacokinetics of Saroglitazar following last dose
| ng/mL | Saroglitazar Magnesium 4 mg |
|---|---|
| Peak Plasma Concentration [Cmax,ss] (For Multiple Dose) | 137.210 ± 57.770 |
Pharmacokinetics of Saroglitazar following last dose
| hour | Saroglitazar Magnesium 4 mg |
|---|---|
| Time to Reach Peak Plasma Concentration [Tmax,ss] (For Multiple Dose) | 1.667 ± 0.866 |
Pharmacokinetics of Saroglitazar following last dose
| ng*hr/mL | Saroglitazar Magnesium 4 mg |
|---|---|
| Area Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval (AUCtau) After Last Dose (For Multiple Dose) | 454.916 ± 162.275 |
Pharmacokinetics of Saroglitazar following last dose
| 1/hr | Saroglitazar Magnesium 4 mg |
|---|---|
| Elimination Rate Constant [Kel,ss] (For Multiple Dose) | 0.147 ± 0.047 |
Pharmacokinetics of Saroglitazar following last dose
| hour | Saroglitazar Magnesium 4 mg |
|---|---|
| Elimination Half-life [Thalf,ss] (For Multiple Dose) | 5.196 ± 1.790 |
Pharmacokinetics of Saroglitazar following last dose
| L | Saroglitazar Magnesium 4 mg |
|---|---|
| Apparent Volume of Distribution [Vd/F,ss] (For Multiple Dose) | 66.047 ± 28.325 |
Pharmacokinetics of Saroglitazar following last dose
| L/hr | Saroglitazar Magnesium 4 mg |
|---|---|
| Apparent Clearance [CL/F,ss] (For Multiple Dose) | 8.883 ± 2.444 |
Pharmacokinetics of Saroglitazar following last dose
| ng/mL | Saroglitazar Magnesium 4 mg |
|---|---|
| Minimal or Trough Plasma Concentration [Cmin] (For Multiple Dose) | 1.053 ± 0.825 |
Pharmacokinetics of Saroglitazar following the last dose. It is calculated as (Cmax - Cmin) / Cavg. The value has been multiplied by 100, hence has been expressed in percentage unit; where Cmax is the Maximum measured plasma concentration at steady state, Cmin is Minimal or trough plasma concentration at steady state, and Cavg is Average concentration = AUCtau,ss /tau.
| percentage | Saroglitazar Magnesium 4 mg |
|---|---|
| Fluctuation Index (For Multiple Dose) | 676.702 ± 240.892 |
Pharmacokinetics of Saroglitazar following last dose
| ratio | Saroglitazar Magnesium 4 mg |
|---|---|
| Accumulation Index Calculated as a Ratio of AUCtau (Last Dose)/AUCtau (First Dose) (For Multiple Dose) | 1.113 ± 0.264 |
Collected over 30 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Saroglitazar Magnesium 4 mg | 0/30 (0%) | 0/30 (0%) | 19/30 (63.3%) |
| Placebo | 0/30 (0%) | 0/30 (0%) | 22/30 (73.3%) |
| Event | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 5/30 | 1/30 |
| General disorders and administration site conditionsGeneral disorders | 3/30 | 4/30 |
| Abdominal painGastrointestinal disorders | 3/30 | 2/30 |
| GastritisGastrointestinal disorders | 3/30 | 0/30 |
| NauseaGastrointestinal disorders | 3/30 | 3/30 |
| VomitingGastrointestinal disorders | 3/30 | 1/30 |
| DiarrheaGastrointestinal disorders | 1/30 | 3/30 |
| Urinary tract infectionInfections and infestations | 3/30 | 1/30 |
| AnxietyPsychiatric disorders | 1/30 | 3/30 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 2/30 | 3/30 |
| Age, Continuous(years) | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|
| Mean | 28.5 ± 7.16 | 27.2 ± 5.79 | 27.9 ± 6.49 |
| Sex: Female, Male(Participants) | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|
| Female | 30 | 30 | 60 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 18 | 21 | 39 |
| Not Hispanic or Latino | 12 | 9 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|
| White | 20 | 15 | 35 |
| Asian | 1 | 1 | 2 |
| Mestizo | 9 | 13 | 22 |
| Other | 0 | 1 | 1 |
| BMI(kg/m^2) | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|
| Mean | 40.14 ± 7.636 | 37.81 ± 6.981 | 38.97 ± 7.348 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in Oct 2024, 68 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Saroglitazar
Non-alcoholic Fatty Liver Disease →